RecruitingNot ApplicableNCT06834633

Nephroprotection in Severe Trauma Patients With Kidney Stress

Impact of a Nephroprotection Bundle-of-care in Severe Trauma Patients at Risk of Acute Kidney Injury: a Multicenter Randomized Controlled Trial


Sponsor

Hospices Civils de Lyon

Enrollment

523 participants

Start Date

Jul 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Acute Kidney Injury (AKI) occurs in 24% of trauma patients, and is even more common in those with severe trauma. It is a major contributor to morbidity and mortality in trauma. Diagnosis of AKI is based on elevated serum creatinine and decreased urine output, two functional markers already indicating the presence of a significant kidney function impairment. Earlier detection of kidney stress, at a preclinical stage when cellular modifications are still reversible, could reduce the occurrence of AKI episodes if nephroprotective measures are rapidly implemented. Several randomized controlled trials have shown that early implementation of such a nephroprotection bundle-of-care in patients at risk of AKI after major surgery reduces the incidence of severe AKI within 72 hours. Although its use is supported by international guidelines, this nephroprotection bundle-of-care is rarely implemented in its totality, due to the significant financial and human resources required for its full implementation. The Nephrocheck® (NC) test is a urine test for which a result \> 0.3 is predictive of AKI development. It might enable early identification of trauma patients at risk of AKI, so that implementation of the nephroprotection bundle-of-care could be targeted solely at those high-risk patients. Thus, the investigators hypothesize that in a population of severe trauma patients (ISS score\>15) at risk of AKI (defined by a NC on Intensive Care Unit (ICU) admission \> 0.3), early implementation of a nephroprotection bundle-of-care would reduce the risk of AKI occurring within 3 days of ICU admission, compared with standard-of-care management. This study will compare the occurrence of AKI in these two groups in a multicenter randomized controlled trial.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Adult patient (≥ 18 years)
  • Severe trauma patients (ISS score > 15) admitted to a trauma center
  • Time between trauma and admission to trauma center <6h
  • Patient with indwelling urinary catheter
  • High risk of AKI: measurement of NC score on fresh urine performed as soon as possible within 12 hours of admission to ICU and value > 0.3.
  • Affiliated with a social security scheme or beneficiary of a similar scheme
  • Consent signed by patient or close relative, or attestation signed by investigator in case of emergency

Exclusion Criteria9

  • Adult under legal protection (guardianship, curators)
  • Persons deprived of their liberty by judicial or administrative decision
  • Patients taking part in other interventional research which may interfere with the research and which includes an exclusion period still in progress at the time of inclusion.
  • Pregnant or breast-feeding woman (diagnosis of pregnancy by plasma βHCG (Beta-Human Chorionic Gonadotropin) assay routinely performed as part of the blood test on admission to the outpatient department of a woman of childbearing age).
  • Patients with end-stage or severe chronic renal failure with Glomerular Filtration Rate (GFR) < 30 milliliters/min/1.73m2 or chronic dialysis.
  • Anuric patients
  • Severe heart failure defined as Left Ventricular Ejection Fraction (LVEF) <25%.
  • Patient moribund on admission with an estimated length of stay of less than 24 hours
  • Patient with AKI at time of randomization (developed prior to ICU admission or within the first 12 hours of ICU admission, before randomization).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERStandard-of-care

Management according to current ICU practices

OTHERSystematic nephroprotection bundle-of-care

The nephroprotection bundle-of-care includes 5 components: 1. Prevention of drugs' nephrotoxicity 2. Hemodynamic optimization, for 24h 3. Blood glucose control and avoidance of hyperglycemia 4. Early detection of rhabdomyolysis 5. Monitoring of renal function


Locations(6)

Centre Hospitalier universitaire Estaing, Service anesthésie-réanimation

Clermont-Ferrand, France

Centre hospitaler Annecy Genevois, Service de réanimation

Épagny, France

Centre hospitalier universitaire de Grenoble Alpes, Pôle anesthésie-réanimation

La Tronche, France

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'anesthésie-réanimation

Lyon, France

Hospices Civils de Lyon, Hôpital Lyon-Sud, Service d'anesthésie-réanimation

Pierre-Bénite, France

Centre hospitalier universitaire de Saint Etienne, Hôpital Bellevue, Service anesthésie-réanimation

Saint-Etienne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06834633